{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-10129"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-10129","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Testing Glutathione-S-Transferase Mu 1 (GSTM1) in Protecting Retinal Pigment Epithelium Cells from Oxidative Stress","abstract":"Currently, the most widely available treatment for wet age-related macular degeneration (AMD) involves the intraocular delivery of biopharmaceuticals, such as anti-VEGF therapy. Drawbacks of this treatment includes a short-term efficacy, requiring repeated injections with additional risks, and a limited availability of options for non-responders. Furthermore, there are no treatments available for patients diagnosed with dry-AMD. The drawbacks and limitations of current therapies represent a need for more effective and permanent therapy as the prevalence of the population affected by AMD is growing. Antioxidant gene therapies are one solution to these implications, protecting the cells from oxidative stress which is one of the major contributing factors of AMD. It has been found that the retina and retinal pigment epithelium (RPE) affected by AMD shows a reduced expression of Glutathione-S-Transferase Mu 1 (GSTM1), a natural antioxidant defense in the body. To this date, no study has been conducted on the protective effects of GSTM1 overexpression in the RPE from oxidative stress. We hypothesize a GSTM1 antioxidant gene therapy on a human retinal pigment epithelial cell line, ARPE-19, will protect cells from oxidative stress implicated in the pathogenesis of AMD.","abstract_html":"Currently, the most widely available treatment for wet age-related macular degeneration (AMD) involves the intraocular delivery of biopharmaceuticals, such as anti-VEGF therapy. Drawbacks of this treatment includes a short-term efficacy, requiring repeated injections with additional risks, and a limited availability of options for non-responders. Furthermore, there are no treatments available for patients diagnosed with dry-AMD. The drawbacks and limitations of current therapies represent a need for more effective and permanent therapy as the prevalence of the population affected by AMD is growing. Antioxidant gene therapies are one solution to these implications, protecting the cells from oxidative stress which is one of the major contributing factors of AMD. It has been found that the retina and retinal pigment epithelium (RPE) affected by AMD shows a reduced expression of Glutathione-S-Transferase Mu 1 (GSTM1), a natural antioxidant defense in the body. To this date, no study has been conducted on the protective effects of GSTM1 overexpression in the RPE from oxidative stress. We hypothesize a GSTM1 antioxidant gene therapy on a human retinal pigment epithelial cell line, ARPE-19, will protect cells from oxidative stress implicated in the pathogenesis of AMD.","abstract_has_math":false,"creators":["Garner, Inyoung C."],"institution":"University of South Florida","degree_name":"Master of Science (M.S.)","degree_level":"Thesis","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":["Manas R. Biswal, M.F.Sc., Ph.D.","Vijaykumar Sutariya, Ph.D., R.Ph.","Nurettin Sahiner, M.Sc., Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-03-13T07:00:00Z","date_published":"2020-03-13T07:00:00Z","updated_at":"2026-11-19T08:44:51Z","subjects":["age-related macular degeneration","antioxidants","cellular detoxification","gene therapy","reactive oxygen species","Nanoscience and Nanotechnology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/8932","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/8932","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-10129","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Manas R. Biswal, M.F.Sc., Ph.D.","Vijaykumar Sutariya, Ph.D., R.Ph.","Nurettin Sahiner, M.Sc., Ph.D."]},{"key":"dc:creator","label":"Author","values":["Garner, Inyoung C."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-03-13T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis","M.S."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (M.S.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["age-related macular degeneration","antioxidants","cellular detoxification","gene therapy","reactive oxygen species","Nanoscience and Nanotechnology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/8932"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Currently, the most widely available treatment for wet age-related macular degeneration (AMD) involves the intraocular delivery of biopharmaceuticals, such as anti-VEGF therapy. Drawbacks of this treatment includes a short-term efficacy, requiring repeated injections with additional risks, and a limited availability of options for non-responders. Furthermore, there are no treatments available for patients diagnosed with dry-AMD. The drawbacks and limitations of current therapies represent a need for more effective and permanent therapy as the prevalence of the population affected by AMD is growing. Antioxidant gene therapies are one solution to these implications, protecting the cells from oxidative stress which is one of the major contributing factors of AMD. It has been found that the retina and retinal pigment epithelium (RPE) affected by AMD shows a reduced expression of Glutathione-S-Transferase Mu 1 (GSTM1), a natural antioxidant defense in the body. To this date, no study has been conducted on the protective effects of GSTM1 overexpression in the RPE from oxidative stress. We hypothesize a GSTM1 antioxidant gene therapy on a human retinal pigment epithelial cell line, ARPE-19, will protect cells from oxidative stress implicated in the pathogenesis of AMD."]},{"key":"dc:title","label":"Title","values":["Testing Glutathione-S-Transferase Mu 1 (GSTM1) in Protecting Retinal Pigment Epithelium Cells from Oxidative Stress"]}]}],"canonical_facts":{"dc:contributor":["Manas R. Biswal, M.F.Sc., Ph.D.","Vijaykumar Sutariya, Ph.D., R.Ph.","Nurettin Sahiner, M.Sc., Ph.D."],"dc:creator":["Garner, Inyoung C."],"dc:date":["2020-03-13T07:00:00Z"],"dc:description":["Currently, the most widely available treatment for wet age-related macular degeneration (AMD) involves the intraocular delivery of biopharmaceuticals, such as anti-VEGF therapy. Drawbacks of this treatment includes a short-term efficacy, requiring repeated injections with additional risks, and a limited availability of options for non-responders. Furthermore, there are no treatments available for patients diagnosed with dry-AMD. The drawbacks and limitations of current therapies represent a need for more effective and permanent therapy as the prevalence of the population affected by AMD is growing. Antioxidant gene therapies are one solution to these implications, protecting the cells from oxidative stress which is one of the major contributing factors of AMD. It has been found that the retina and retinal pigment epithelium (RPE) affected by AMD shows a reduced expression of Glutathione-S-Transferase Mu 1 (GSTM1), a natural antioxidant defense in the body. To this date, no study has been conducted on the protective effects of GSTM1 overexpression in the RPE from oxidative stress. We hypothesize a GSTM1 antioxidant gene therapy on a human retinal pigment epithelial cell line, ARPE-19, will protect cells from oxidative stress implicated in the pathogenesis of AMD."],"dc:identifier":["https://digitalcommons.usf.edu/etd/8932"],"dc:subject":["age-related macular degeneration","antioxidants","cellular detoxification","gene therapy","reactive oxygen species","Nanoscience and Nanotechnology"],"dc:title":["Testing Glutathione-S-Transferase Mu 1 (GSTM1) in Protecting Retinal Pigment Epithelium Cells from Oxidative Stress"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["Thesis","M.S."],"thesis:degree_name":["Master of Science (M.S.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:44:51Z"}